PRKCB and diffuse large B-cell lymphoma: Enzastaurin (ENZ), an oral PKC-β and Akt inhibitor, failed to extend OS in the large phase III “PRELUDE” trial as a maintenance therapy for high-risk DLBCL patients (IPI ≥ 3) who achieved a CR after R-CHOP induction [125].